| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Liu,Zhi-Ping | Chairman | 0.37% | |
| Fan,Zi-Ting | Vice Chairman | 29.89% | STANDARD CHEM. & PHARM. CO., LTD. |
| Wen,De-Lan | Director | 46.59% | ROSSMAX INTERNATIONAL LTD. |
| Zhang,Shu-Juan | Director | 46.59% | ROSSMAX INTERNATIONAL LTD. |
| Ye,Cui-Wen | Director | 0.00% | |
| Zheng,Zhen-Wen | Director | 0.00% | |
| Chen,Hong-Yun | Independent Director | 0.00% | |
| Han,Zong-Chao | Independent Director | 0.00% | |
| Ou,Xiu-Zhu | Independent Director | 0.00% |
Change Company Name to WE CAN MEDICINES CO., LTD.
2024/05/30
Change Person in Charge to Liu,Zhi-Ping
2024/05/30
Change Company Name to YOUQUAN PHARMACEUTICAL CO., LTD. (FORMER NAME: SHENGLIN PHARMACEUTICAL CO., LTD.)
2022/10/14
Change Company Name to YOUQUAN PHARMACEUTICAL CO., LTD. (FORMER NAME: SHENGLIN PHARMACEUTICAL CO., LTD.)
2022/06/13
Change Company Name to WE CAN MEDICINES CO., LTD.
2022/06/13
Change Capital to 1,000,000,000
2021/06/09
Change Capital to 400,000,000
2013/11/18
Change Person in Charge to Zheng,Zhen-Wen
2013/06/26
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 797,872 | 3,269,204 | 3,122,894 |
| Operating cost | 528,293 | 2,165,294 | 2,099,433 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 269,579 | 1,103,910 | 1,023,461 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 269,579 | 1,103,910 | 1,023,461 |
| Operating expenses | 280,823 | 1,153,921 | 999,518 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -11,244 | -50,011 | 23,943 |
| Non-operating income and expenses | -1,181 | 1,717 | -2,341 |
| Net profit (loss) before tax | -12,425 | -48,294 | 21,602 |
| Income tax expense (benefits) | 0 | -1,118 | 6,799 |
| Net profit (loss) of ongoing business for the current period | -12,425 | -47,176 | 14,803 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -12,425 | -47,176 | 14,803 |
| Other comprehensive profit (loss), net | - | -2,452 | -120 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -12,425 | -49,628 | 14,683 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | -1 | 0 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 30,233 | - | - |
| Net cash inflows (outflows) from investing activities | -5,672 | - | - |
| Net cash inflow (outflow) from financing activities | -66,100 | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | -41,539 | - | - |
| Beginning balance of cash and cash equivalents | 305,670 | - | - |
| Ending balance of cash and cash equivalents | 264,131 | - | - |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,396,192 | 1,464,623 | 1,291,531 |
| Non-current asset | 1,656,324 | 1,620,971 | 1,569,322 |
| Total asset | 3,052,516 | 3,085,594 | 2,860,853 |
| Current liability | 865,961 | 921,387 | 1,045,095 |
| Non-current liability | 1,080,359 | 1,048,049 | 999,411 |
| Total liability | 1,946,320 | 1,969,436 | 2,044,506 |
| share capital | 450,138 | 450,181 | 400,000 |
| Equity - secruity token | - | - | - |
| capital reserve | 667,292 | 664,786 | 353,528 |
| retained earning | -11,234 | 1,191 | 62,819 |
| Other equity | 0 | 0 | 0 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,106,196 | 1,116,158 | 816,347 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 17,000 | 60,500 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 24 | 24 | 20 |
